Select therapeutic use:
Indications for ZOSTAVAX:
Prevention of herpes zoster (shingles) in adults ≥50 years of age.
Limitations Of use:
Not for treating zoster or postherpetic neuralgia. Not for preventing primary varicella infection.
<50yrs: not recommended. ≥50yrs: one 0.65mL dose by SC inj once in upper arm. Administer immediately upon reconstitution.
Immunodeficiency (eg, HIV, leukemia, lymphoma, bone marrow or lymphatic cancer, immunosuppressive therapy). Pregnancy (during and 3 months after vaccination).
Have epinephrine inj (1:1000) available. Consider deferral in acute illness or acute untreated tuberculosis. May not protect 100% of recipients. Virus transmission may occur between recipients and susceptible contacts. Nursing mothers.
See Contraindications. Immunosuppressants may cause disseminated disease. Consider administration of Zostavax and Pneumovax 23 vaccines separated by ≥4 weeks. Concomitant inactivated influenza vaccines: see full labeling.
Inj site reactions (eg, erythema, pain, swelling, pruritus), headache; cardiovascular events.
To report adverse events, contact VAERS at (800) 822-7967.
Single-dose vials—1, 10 (w. diluent)